VACCINES BASED ON VIRUS-LIKE PARTICLES (VLP) OF CANINE PARVOVIRUS (CPV) AND APPLICATION THEREOF Russian patent published in 2020 - IPC A61K39/12 A61K39/135 A61K39/23 A61P31/00 

FIELD: biotechnology.

SUBSTANCE: group of inventions refers to immunology, namely to production of a combined vaccine against canine parvovirus. Combined vaccine comprising a component in the form of a virus-like particle (VLP) and a component in the form of a modified live virus (MLV), in which both VLP and MLV are directed against the same pathogen or disease, where the combined vaccine overcomes the action of maternal antibodies (MDA), in which the VLP CPV comprises a CPV polypeptide having a sequence as given in SEQ ID NO: 1, 3, 4, 6, 8, 9 or 10; or in which the CPV VLP comprises a CPV polypeptide, having at least 96 % identity with the sequence as given in SEQ ID NO: 1, 3, 4, 6, 8, 9 or 10. Group of inventions also relates to a plasmid useful for producing VLP CPV, purified empty CPV capsid and a method for inducing an anti-CPV immune response in an animal.

EFFECT: use of this group of inventions enables to elicit an immune response in vaccinated animals regardless of the presence of high levels of maternal anti-CPV antibodies in said animals.

18 cl, 19 dwg, 14 tbl, 8 ex